Onkologie. 2011:5(4):204-206

Targeted therapy of renal carcinoma

Hana Procházková-Študentová, Bohuslav Melichar
Onkologická klinika LF UP a FN Olomouc

Renal cancer differs from other tumours by its biological behaviour, having an impact on its therapeutic approach. Due to chemoresistance,

targeted therapy plays a major role in the treatment of renal carcinoma, targeting mainly vascular endothelial growth factor,

a keystone in renal carcinoma etiopathogenesis and progression.

Keywords: renal cell carcinoma, chemoresistance, targeted therapy, VEGF

Published: December 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Procházková-Študentová H, Melichar B. Targeted therapy of renal carcinoma. Onkologie. 2011;5(4):204-206.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Mickisch GH, Roehrich K, Koessig J, Forster S, Tschada RK, Alken PM. Mechanisms and modulation of multidrug resistance in primary human renal cell carcinoma. J Urol 1990; 144(3): 755-9. Go to original source... Go to PubMed...
    2. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma, J Urol 2000; 163: 408-417. Go to original source... Go to PubMed...
    3. Yagoda A, Petrylak D, Thompson S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin N Am 1993; 20: 303-321. Go to original source...
    4. Medical Reseach Council Renal Cancer Colaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomized controlled trial. Lancet 1999; 353: 14-17. Go to original source...
    5. Atzpodien J, Kirchner H, IIliger HJ, et al. IL-2 in combination with with INF-alfa and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trials. Br J Cancer 2001; 85: 1130-1136. Go to original source... Go to PubMed...
    6. Takahashi A, Sasaki H, Kim SJ, et al. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res 1994; 54: 4233-4237.
    7. Papac RJ, Poo-Hwu WJ. Renal cell carcinoma: A paradigm of lanthanic disease. Am J Clin Oncol 1999; 22: 223-231. Go to original source... Go to PubMed...
    8. Lokich J. Spontaneous regression of metastatic renal cancer. Case report and literature review. Am J Clin Oncol 1997; 20(4): 416-418. Go to original source... Go to PubMed...
    9. Freed SZ, Halperin JP, Gordon M. Idiopathic regression of metastases from renal cell carcinoma. J Urol 1977; 118(4): 583-542. Go to original source... Go to PubMed...
    10. Marcus SG, Choyke PL, Reiter R, Jaffe GS, Alexander RB, Linehan WM, Rosenberg SA, Walter MM. Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy. J Urol 1993; 150: 463-436. Go to original source... Go to PubMed...
    11. Wyczolkowski M, Klima W, Bieda W. Walas K. Spontaneous regression of hepatic metastases after nephrectomy and metastasectomy of renal cell carcinoma. Urol Int 2001; 66: 119-120. Go to original source... Go to PubMed...
    12. Gleave ME, Elhilali M, Fradet Y, et al. Interferon gamma1b compared with placebo in metastatic renal-cell carcinoma. N Engl J Med 1998; 338: 1265-1271. Go to original source... Go to PubMed...
    13. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 pacients with advanced renal cell carcinoma. J Clin Oncol 1999; 17: 2530-2540. Go to original source... Go to PubMed...
    14. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001; 345: 1655-1659. Go to original source... Go to PubMed...
    15. Mickish GHJ, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001; 358: 966-970. Go to original source... Go to PubMed...
    16. Bennet RT, Lerner SE, Taub HC, Dutcher JP, Fleischamnn J. Cytoreductive surgery for stage IV renal cell carcinoma. J Urol 1995; 154: 32-34. Go to original source... Go to PubMed...
    17. Gatenby RA, Gawlinski ET, Tangen CM, Flanigan RC, Crawford ED. The possible role of postoperative azotemia in enhanced survival of patients with metastatic renal cancer after cytoreductive nephrectomy. Cancer Res 2002; 62: 5218-5222.
    18. Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS. Resection of metastatic renal cell carcinoma. J Clin Oncol 1998; 16: 2261-2266. Go to original source... Go to PubMed...
    19. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-VEGF antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-434. Go to original source... Go to PubMed...
    20. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295: 2516-2524. Go to original source... Go to PubMed...
    21. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 16-24. Go to original source... Go to PubMed...
    22. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134. Go to original source... Go to PubMed...
    23. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28: 1061-1068. Go to original source... Go to PubMed...
    24. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103-2111. Go to original source... Go to PubMed...
    25. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008; 26: 5422-5428. Go to original source... Go to PubMed...
    26. Melichar B, Koralewski P, Ravaud A, et al. First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma. Ann Oncol 2008; 19: 1470-1476. Go to original source... Go to PubMed...
    27. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124. Go to original source... Go to PubMed...
    28. Rini BI, Michaelson MD, Rosenberg JE, et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008; 26: 3743-3748. Go to original source... Go to PubMed...
    29. Dudek AZ, Zolnierek J, Dham A, Lindgren BR, Szcylik C. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 2009; 115: 61-67. Go to original source... Go to PubMed...
    30. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of ramapycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 2: 909-918. Go to original source... Go to PubMed...
    31. Hudes G, Garducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281. Go to original source... Go to PubMed...
    32. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-456. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.